Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT03936153 by Xynomic Pharmaceuticals, Inc., with 170 participants planned, started 2020-01-20 and due to reach its primary completion in 2026-07-31. Interventions recorded: abexinostat. Conditions listed: Diffuse Large B-cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.